85例颅外转移性乳腺癌放疗疗效观察及预后分析

doi:10.3760/cma.j.cn113030-20200825-00438

Abstract
Figure/Table
References()
Related Citation (15)
Read Tracking
Download Tracking

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS) Supporting Info

Abstract Objective To evaluate the clinical efficacy of radiotherapy in the treatment of extracranial metastatic breast cancer, and to investigate the significance and prognostic factors of whole-lesion radiotherapy (WLRT). Methods Clinical data of 85 patients with extracranial metastatic breast cancer treated with radiotherapy between 2014 and 2019 were retrospectively analyzed. Thirty-six patients were assigned into the WLRT group and 49 in the non-WLRT group. The local control (LC), progression-free survival (PFS) and overall survival (OS) were calculated by Kaplan-Meier method, log-rank test and univariate prognostic analysis. Cox proportional hazards model was used for multivariate prognostic analysis. Results The median follow-up time was 26.7 months. The 2-year LC, PFS, OS rates were 77%, 26%, 77%, respectively. The 2-year LC (91% vs. 67%, P=0.001), PFS (47% vs. 8%,P<0.001), OS rates (84% vs. 71%, P=0.010) in the WLRT group were significantly higher than those in the non-WLRT group, respectively. Multivariate analysis demonstrated that WLRT was an independent favorable prognostic factor for the LC, PFS and OS. Furthermore, bone metastasis alone was associated with improved LC and positive hormone receptor status was correlated with improved OS. Conclusions WLRT has the potential to prolong the survival of patients with extracranial metastatic breast cancer. The patients with bone metastases alone obtain better LC, whereas those with negative hormone receptor status has worse OS.

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Song Yuchun
	Fang Hui
	Wang Shulian
	Xiao Jianping
	Tang Yu
	Liu Yueping
	Song Yongwen
	Chen Bo
	Qi Shunan
	Li Ning
	Tang Yuan
	Jing Hao
	Yang Yong
	Ren Hua
	Zhao Ruizhi
	Lu Ningning
	Jin Jing
	Li Yexiong

Key words： Extracranial metastasis, breast neoplasm/radiotherapy Whole lesion Prognosis

Received: 25 August 2020

Fund:Beijing Marathon of Hope, Cancer Foundation of China (LC2020A32)

Corresponding Authors: Fang Hui, Email:fanghuii@163.com;Wang Shulian, Email:wsl20040118@yahoo.com

Cite this article:

Song Yuchun,Fang Hui,Wang Shulian et al. Clinical efficacy and prognosis of 85 patients with extracranial metastatic breast cancer receiving radiotherapy[J]. Chinese Journal of Radiation Oncology, 2021, 30(6): 569-574.

URL:

http://journal12.magtechjournal.com/Jweb_fszlx/EN/10.3760/cma.j.cn113030-20200825-00438 OR http://journal12.magtechjournal.com/Jweb_fszlx/EN/Y2021/V30/I6/569

[1] Early Breast Cancer Trialists' Collaborative G. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:an overview of the randomised trials[J]. Lancet, 2005, 365(9472):1687-1717.DOI:10.1016/S0140-6736(05)66544-0.
[2] Giordano SH, Buzdar AU, Smith TL, et al. Is breast cancer survival improving?[J]. Cancer, 2004, 100(1):44-52. DOI:10.1002/cncr.11859.
[3] Chia SK, Speers CH, D'Yachkova Y, et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer[J]. Cancer, 2007, 110(5):973-979. DOI:10.1002/cncr.22867.
[4] Pagani O, Senkus E, Wood W, et al. International guidelines for management of metastatic breast cancer:can metastatic breast cancer be cured?[J]. J Natl Cancer Inst, 2010, 102(7):456-463.DOI:10.1093/jnci/djq029.
[5] Hu XC, Zhang J, Xu BH, et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006)):a randomised, open-label, multicentre, phase 3 trial[J]. Lancet Oncol, 2015, 16(4):436-446.DOI:10.1016/S1470-2045(15)70064-1.
[6] Fan Y, Xu BH, Yuan P, et al. Docetaxel-cisplatin might be superior to docetaxel-capecitabine in the first-line treatment of metastatic triple-negative breast cancer[J]. Ann Oncol, 2013, 24(5):1219-1225. DOI:10.1093/annonc/mds603.
[7] Bergh J, Jönsson PE, Lidbrink EK, et al. FACT:an open-label randomized phase Ⅲ study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer[J]. J Clin Oncol, 2012, 30(16):1919-1925. DOI:10.1200/JCO.2011.38.1095.
[8] Gianni L, Romieu GH, Lichinitser M, et al. AVEREL:a randomized phase Ⅲ Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER-2-positive locally recurrent/metastatic breast cancer[J]. J Clin Oncol, 2013, 31(14):1719-1725. DOI:10.1200/JCO.2012.44.7912.
[9] Trovo M, Furlan C, Polesel J, et al. Radical radiation therapy for oligometastatic breast cancer:Results of a prospective phase Ⅱ trial[J]. Radiother Oncol, 2018, 126(1):177-180.DOI:10.1016/j.radonc.2017.08.032.
[10] Milano MT, Zhang H, Metcalfe SK, et al. Oligometastatic breast cancer treated with curative-intent stereotactic body radiation therapy[J]. Breast Cancer Res Treat, 2009, 115(3):601-608. DOI:10.1007/s10549-008-0157-4.
[11] Kobayashi T, Ichiba T, Sakuyama T, et al. Possible clinical cure of metastatic breast cancer:lessons from our 30-year experience with oligometastatic breast cancer patients and literature review[J]. Breast Cancer, 2012, 19(3):218-237.DOI:10.1007/s12282-012-0347-0.
[12] Yoo GS, Yu JI, Park W, et al. Prognostic factors in breast cancer with extracranial oligometastases and the appropriate role of radiation therapy[J]. Radiat Oncol J, 2015, 33(4):301-309. DOI:10.3857/roj.2015.33.4.301.
[13] Lutz S, Balboni T, Jones J, et al. Palliative radiation therapy for bone metastases:Update of an ASTRO Evidence-Based Guideline[J]. Pract Radiat Oncol, 2017, 7(1):4-12. DOI:10.1016/j.prro.2016.08.001.
[14] Chow E, Harris K, Fan G, et al. Palliative radiotherapy trials for bone metastases:a systematic review[J]. J Clin Oncol, 2007, 25(11):1423-1436.DOI:10.1200/JCO.2006.09.5281.
[15] Mole RH. Whole body irradiation;radiobiology or medicine?[J]. Br J Radiol, 1953, 26(305):234-241.DOI:10.1259/0007-1285-26-305-234.
[16] Postow MA, Callahan MK, Barker CA, et al. Immunologic correlates of the abscopal effect in a patient with melanoma[J]. N Engl J Med, 2012, 366(10):925-931.DOI:10.1056/NEJMoa1112824.
[17] Kwon ED, Drake CG, Scher HI, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043)):a multicentre, randomised, double-blind, phase 3 trial[J]. Lancet Oncol, 2014, 15(7):700-712. DOI:10.1016/S1470-2045(14)70189-5.
[18] Mcbride SM, Sherman EJ, Tsai CJ, et al. A phase Ⅱ randomized trial of nivolumab with stereotactic body radiotherapy (SBRT) versus nivolumab alone in metastatic (M1) head and neck squamous cell carcinoma (HNSCC)[J]. J Clin Oncol, 2018, 36(15_suppl):6009-6009. DOI:10.1200/JCO.2018.36.15_suppl.6009.
[19] Theelen W, Lalezari F, Michel VDH, et al. Randomized phase Ⅱ study of pembrolizumab after SBRT versus pembrolizumab alone in patients with advanced NSCLC, preliminary results[J]. J Thorac Oncol, 2017, 12(1):S1453.DOI:10.1016/j.jtho.2016.11.1983.
[20] Gomez DR, Blumenschein GR Jr, Lee JJ, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy:a multicentre, randomised, controlled, phase 2study[J]. Lancet Oncol, 2016, 17(12):1672-1682. DOI:10.1016/S1470-2045(16)30532-0.
[21] Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET)):a randomised, phase 2, open-label trial[J]. Lancet, 2019, 393(10185):2051-2058. DOI:10.1016/S0140-6736(18)32487-5.
[22] Murabito M, Salat A,Mueller MR. Complete resection of isolated lung metastasis from breast carcinoma results in a strong increase in survival[J]. Minerva Chir, 2000, 55(3):121-127.DOI:10.1016/j.virusres.2011.04.012.
[23] Brooks ED, Chang JY. Time to abandon single-site irradiation for inducing abscopal effects[J]. Nat Rev Clin Oncol, 2019, 16(2):123-135. DOI:10.1038/s41571-018-0119-7.
[24] Huang AC, Postow MA, Orlowski RJ, et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response[J]. Nature, 2017, 545(7652):60-65. DOI:10.1038/nature22079.
[25] Kuru B, Camlibel M, Dinc S, et al. Prognostic factors for survival in breast cancer patients who developed distant metastasis subsequent to definitive surgery[J]. Singapore Med J, 2008, 49(11):904-911.DOI:10.1016/j.revmed.2008.02.019.
[26] James JJ, Evans AJ, Pinder SE, et al. Bone metastases from breast carcinoma:histopathological-radiological correlations and prognostic features[J]. Br J Cancer, 2003, 89(4):660-665. DOI:10.1038/sj.bjc.6601198.
[27] Gong Y, Liu YR, Ji P, et al. Impact of molecular subtypes on metastatic breast cancer patients:a SEER population-based study[J]. Sci Rep, 2017, 7:45411.DOI:10.1038/srep45411.
[28] Lobbezoo DJ, van Kampen RJ, Voogd AC, et al. Prognosis of metastatic breast cancer subtypes:the hormone receptor/HER-2-positive subtype is associated with the most favorable outcome[J]. Breast Cancer Res Treat, 2013, 141(3):507-514.DOI:10.1007/s10549-013-2711-y.
[29] Milano MT, Katz AW, Zhang H, et al. Oligometastases treated with stereotactic body radiotherapy:long-term follow-up of prospective study[J]. Int J Radiat Oncol Biol Phys, 2012, 83(3):878-886.DOI:10.1016/j.ijrobp.2011.08.036.